Novel antivirals for severe enterovirus infection in immunocompromised hosts; a case series

Andrea Meinhardt,Liam Reilly,Marios Kaliakatsos,Khaled Abdel-Aziz,Sondus Alsharidah,Istvan Bodi,Claire Booth,Kritika Chetty,Jennifer Evans,Laura Ferreras-Antolín,Susannah Froude,Clare M Galtrey,Suba Guruprasad,Robert D Hadden,Jane Hassell,Heikki Hyöty,Alexandra Y. Kreins,Jutta E. Laiho,David M Lowe,Michael P Lunn,Kshitij Mankad,Siske Struik,Elizabeth Whittaker,Austen Worth,Patrick Yong,Liqun Zhang,Judith Breuer,Seilesh Kadambari
DOI: https://doi.org/10.1016/j.jinf.2024.106142
IF: 28.2
2024-03-28
Journal of Infection
Abstract:Highlights • Enteroviruses can cause significant morbidity and mortality in immunocompromised. • Serial tests in multiple compartments may be necessary to identify Enterovirus. • Metagenomics on brain biopsy may be justified when conventional testing is negative. • Early combination antiviral treatments can improve outcomes in immunocompromised. • Antiviral therapy acts as bridging therapy until immune reconstitution.
infectious diseases
What problem does this paper attempt to address?